Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
Sold 10k at 4.25. Rebought them at 3.90. And instantly having buyers remorse. Thinking this could possibly slide down to 3.60 tomorrow..oh well, let’s ride
-
Trash management, trash results.
-
-
Surely that’s not the freaking news.
-
-
The problem with this stock is management.
-
Bears talk shit because you let them know they bother you by posting your whiny complaints about them.
-
Alway funny to see morons saying “I’ll never sell at any price”.
-
They drop PR and price runs up to $10, giving them approval for the 100 million new shares. Which makes the shares instantly available to exercise (sell) since the price is at the $10 limit they stated. Instant one billion dollars in their pockets and instant stock dilution. Price drops back to $3 range.
-
I voted No. fuck your opinion
-
Will be in the 3.30s tomorrow. Trash management
-
$3.35 tomorrow.
-
Jack, it’s still dilution no matter how you want to spin it. Once the shares have been approved it’s dilution. Surely you aren’t this naive…
-
You don’t know what they are going to do with the shares, but dilution is dilution no matter how you want to sugar coat it. And the fact that they have remained silent even with the lawsuit throws up red flags. Almost like they are trying to get one last massive payday so they get paid no matter what.
-
Leadership is nonexistent in this company. Good potential on their products, but completely undermined by their lack of communication. Any semblance of PR and this would easily stay in the $6 range instead of where it’s at. Perhaps they are going to release something a few days prior to the vote, but should have never let the price drop this far to begin with.
-
From $9.80 to $3.55. And now wanting to dilute the float by 100 million despite giving shareholders ZERO updates.
-
Complete ineptness from management.
-
No interest in the 9/3 $4 calls. Wow.
-
Just ANY FUCKING WORD from management would help this tremendously. Anything at all.
-
Yet, EDDIE BROWN was pitching the NO vote just two weeks ago lmao. Eddie is a clown who just likes to read his own posts. He flipflops constantly.
-
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
news.google.com • -
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •